Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04340141 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started2020-10-13
View on ClinicalTrials.gov ↗

Amendment history

2026-09-02
Study Status, Contacts/Locations v24
Study sitesdetails revised at 1 of 453 sites
2026-08-31
Study Status, Conditions, Arms and Interventions, Eligibility, Contacts/Locations v23
Eligibility criteria+16 characters
[...] ancy test done =< 14 days prior to registration is required Age >= 18 years Eastern Cooperative Oncology Group (ECOG) performance status [...]
Study sitesdetails revised at 1 of 453 sites
2026-02-09
Study Status v22
Primary completion date2027-01-01→2028-12-31
2026-02-03
Study Status, Contacts/Locations v21
Study sites454→453
2026-01-26
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v20
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2026-01-01→2027-01-01
Enrollment targetestimated 352→confirmed 358
Study sitesdetails revised at 454 of 454 sites
Show 19 earlier versions
2026-01-06
Study Status, Contacts/Locations v19
Study sites454 entries, revised
University of Michigan ComprehensiveRogel Cancer Center
2025-12-02
Study Status, Contacts/Locations v18
Study sites453→454
2025-11-04
Study Status, Contacts/Locations v17
Study sites451→453
2025-10-07
Study Status, Contacts/Locations v16
Study sitesdetails revised at 16 of 451 sites
2025-08-28
Study Status, Contacts/Locations v15
Study sites450→451
2025-06-24
Study Status, Contacts/Locations v14
Study sitesdetails revised at 25 of 450 sites
2025-03-28
Study Status, Contacts/Locations v13
Study sites449→450
2025-01-09
Study Status, Contacts/Locations v12
Primary completion date2026-01→2026-01-01
Completion date2030-11→2030-11-01
Start date2020-07-01→2020-10-13
Study sitesdetails revised at 267 of 449 sites
2024-12-24
Study Status, Contacts/Locations v11
Study sites446→449
2024-10-24
Study Status, Contacts/Locations v10
Study sites437→446
2024-08-01
Study Status, Contacts/Locations v9
Study sites421→437
2024-05-22
Study Status, Contacts/Locations v8
Study sites418→421
2024-04-08
Study Status, Contacts/Locations v7
Study sites417→418
2024-02-19
Study Status, Contacts/Locations v6
Study sites411→417
2023-10-30
Study Status, Contacts/Locations v5
Study sites404→411
2023-08-30
Study Status, Contacts/Locations v4
Study sites183→404
2022-08-01
Study Status v3
Re-verified, no change to tracked fields
2020-10-01
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-07→confirmed 2020-07-01
Study sites0→183
2020-04-15
Study Status, Outcome Measures v1
Secondary endpointsdetails revised at 1 of 15 entries
2020-04-07
Original filing
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Trial Details
NCT Number NCT04340141
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Enrollment 358 participants
Start Date 2020-10-13
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-04